Tuberculosis (TB) is a global health hazard leading to several deaths. In 2020, about 10 million people had TB, out of which 1.5 million died; its incidence will increase in 2022-23 owing to COVID-19 infection. Additionally, a large number of cases of multidrug or rifampicin-resistant tuberculosis (MDR/RR-TB) and drug-resistant TB (DR-TB), including extensively drug-resistant TB (XDR-TB) and pre-XDR-TB, emerge every year. Using the international Grading of Recommendations Assessment, Development and Evaluation (GRADE5) approach, the WHO Global Tuberculosis Programme (WHO/GTB) has issued evidence-based guidelines for treating TB.
Diagnostic Approaches Rapid molecular test, namely Xpert Ultra, is preferred as the initial test for TB in children and adolescents. Strong recommendation Noninvasive specimens, such as stool samples, can be included in diagnostic tests. Strong…
